Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study
Headache: The Journal of Head and Face Pain · 2025
DOI: 10.1111/head.14913 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2025. Verfasst von Alba López-Bravo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Hospital Reina Sofia, Tudela, Navarra, Spain. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide, Migraine Disorders. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Calcitonin gene‐related peptide monoclonal antibodies (CGRP mAbs) are the first migraine‐specific prophylactic medication. Clinical data regarding patient treatment satisfaction (TS) with CGRP mAbs are limited.
Methods
A multicenter prospective cohort study was conducted in patients with ≥8 headache days/month who started treatment with erenumab, galcanezumab, or fremanezumab. Monthly migraine days (MMD), monthly headache days (MHD), Migraine Disability Assessment (MIDAS), and the six‐item Headache Impact Test (HIT‐6) scores were collected. Patients’ satisfaction with treatment (effectiveness, convenience, side effects, and global satisfaction) was assessed by the Treatment Satisfaction Questionnaire for Medication, version 1.4 (TSQM‐1.4©).
Results
A total of 400 patients were included. The median (interquartile range [IQR]) TS scores were high (≥70%) across all domains of the TSQM‐1.4 after 3 and 6 months of CGRP mAb therapy: 72.2 (50.0–83.3) and 83.3 (61.1–88.9) for effectiveness, 83.3 (72.2–100) and 83.3 (77.8–100) for convenience, and finally, a score of 78.6 (50.0–92.9) and 85.7 (71.4–92.9) for global satisfaction. The median (IQR) reduction in MHD and MMD was 10.0 (3.0–17.0; p < 0.001) and 8.0 (4.0–12.0; p < 0.001) days after 3 months of treatment, and 10.0 (3.0–17.0; p < 0.001) and 9.0 (5.0–17.0; p < 0.001) days after 6 months. The median (IQR) HIT‐6 score decreased from 68.0 (65.0–72.0) to 60.0 (51.0–66.0; p < 0.001) at Month 3 and to 56.0 (48.0–64.0; p < 0.001) at Month 6. Finally, the median (IQR) MIDAS score decreased from 70 (40.0–120.0) to 24 (7.8–60.0; p < 0.001) and 17 (5.0–45.0; p < 0.001) at Months 3 and 6, respectively. The median change from baseline in MMD was significantly associated with effectiveness at 3 ( β = −0.93, 95% CI −1.34 to −0.53; p < 0.001) and 6 months ( β = −1.56, 95% CI −2.15 to −0.97; p < 0.001). Similarly, reductions in MMD were significantly associated with the global satisfaction dimension of the questionnaire ( β = −0.82, 95% CI −1.27 to −0.37; p < 0.001) and ( β = −1.80, 95% CI −2.42 to −1.18; p < 0.001).
Conclusions
Most patients were satisfied with CGRP mAbs’ effectiveness, tolerability, and convenience in a real‐world setting. Interestingly, increasing TS was associated with meaningful reductions in frequency, impact, and disability caused by migraine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology Department, Hospital Reina Sofia, Tudela, Navarra, Spain.
- Aragon Institute for Health Research (IIS Aragón), Zaragoza, Spain.
- Department of Health Sciences, Public University of Navarra, Pamplona, Spain.
- Neurology Department, Hospital Universitario Donostia, San Sebastian, Spain.
- Neurology Department, La Fe University and Polytechnic Hospital, Valencia, Spain.
- Headache and Neuralgia Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
ORCID-Profile: Alba López-Bravo, Noemí Morollón Sánchez-Mateos, María Pilar Navarro-Pérez, David García-Azorín, Alicia González-Martínez, Sonia Santos-Lasaosa
Zitieren
APA
López-Bravo, A., Mínguez-Olaondo, A., Nieves-Castellanos, C., Ruibal-Salgado, M., Sánchez-Mateos, N. M., Navarro-Pérez, M. P., Alpuente, A., Torres-Ferrús, M., García-Ull, J., Gago-Veiga, A., García-Azorín, D., González-Martínez, A., Sierra, Á., & Santos-Lasaosa, S. (2025). Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14913
Vancouver
López-Bravo A, Mínguez-Olaondo A, Nieves-Castellanos C, Ruibal-Salgado M, Sánchez-Mateos NM, Navarro-Pérez MP, et al. Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.14913
BibTeX
@article{LpezBravo2025,
author = {López-Bravo, Alba and Mínguez-Olaondo, Ane and Nieves-Castellanos, Candela and Ruibal-Salgado, Marta and Sánchez-Mateos, Noemí Morollón and Navarro-Pérez, María Pilar and Alpuente, Alicia and Torres-Ferrús, Marta and García-Ull, Jésica and Gago-Veiga, Ana and García-Azorín, David and González-Martínez, Alicia and Sierra, Álvaro and Santos-Lasaosa, Sonia},
title = {Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study},
journal = {Headache: The Journal of Head and Face Pain},
year = {2025},
doi = {10.1111/head.14913}
}
EUVIMED